Phosphodietserases-5 inhibitors (PDE5is) are currently the first line oral treatment for erectile dysfunction (ED) even though they can have potential role in slowing down plaque formation in Peyronie’s disease (PD). Several studies on animal models showed that PDE5is have anti-fibrotic properties that might help to relieve fibrotic plaques along with diffused corpora cavernosa fibrosis. Moreover, clinical studies using PDE5is alone or in combination with other medical treatments have shown promising results in reducing plaque fibrosis in patients with PD. Additionally, PDE5is play a fundamental role in patients developing ED after PD onset due to penile deformity, pain, narrowing, shortening and, curvature upon erections. Likewise, ED can occur after surgery for PD; in this context PDE5is are vital to restore proper erectile function.
PDE5i therapy / Pozzi, E.; Capogrosso, P.; Salonia, A.. - (2020), pp. 131-140. [10.1016/B978-0-12-819468-3.00011-2]
PDE5i therapy
Pozzi E.Primo
;Salonia A.Ultimo
2020-01-01
Abstract
Phosphodietserases-5 inhibitors (PDE5is) are currently the first line oral treatment for erectile dysfunction (ED) even though they can have potential role in slowing down plaque formation in Peyronie’s disease (PD). Several studies on animal models showed that PDE5is have anti-fibrotic properties that might help to relieve fibrotic plaques along with diffused corpora cavernosa fibrosis. Moreover, clinical studies using PDE5is alone or in combination with other medical treatments have shown promising results in reducing plaque fibrosis in patients with PD. Additionally, PDE5is play a fundamental role in patients developing ED after PD onset due to penile deformity, pain, narrowing, shortening and, curvature upon erections. Likewise, ED can occur after surgery for PD; in this context PDE5is are vital to restore proper erectile function.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
